Search Results
Oct 20, 2025, 08:00 ET Randall Atkins Appointed to Executive Committee of IEA's Coal Industry Advisory Board
advocacy for the strategic role of coal in the global energy supply chain. The CIAB, established in 1979, is a high-level advisory body composed of senior executives from coal-related industries across 13 countries, representing nearly 80% of global coal production and consumption. Its
More news about: Ramaco Resources, Inc.
Oct 20, 2025, 08:00 ET RINVOQ® (upadacitinib) Demonstrated Superiority Versus HUMIRA® (adalimumab) for Primary Endpoint in a Head-to-Head Study in Rheumatoid Arthritis Patients Who Have Failed First TNF Inhibitor
switching to a different mode of action after the first TNFi failure.7-15 "These positive results strengthen the growing body of evidence supporting the benefits of switching to a new mechanism of action after inadequate response or intolerance to a first TNF inhibitor," said
More news about: AbbVie
Oct 20, 2025, 08:00 ET The Jackson Laboratory acquires New York Stem Cell Foundation to transform biomedical research and accelerate precision therapies for patients
often derail later-stage clinical trials." In practice, induced pluripotent stem cells can be transformed into any cell in the body, including brain cells to study Alzheimer's and ALS, or cardiomyocytes to study heart disease. With JAX's genetically diverse mouse models and NYSCF's
More news about: The Jackson Laboratory
Oct 20, 2025, 07:49 ET Lymph System Support Supplements Help Remove Cellular Waste and Toxins
Lymph System Support supplements help the body remove cellular waste and toxins through optimized lymphatic drainage. The company's comprehensive supplement collection features scientifically
More news about: PureHealth Research
Oct 20, 2025, 07:30 ET Endo Launches First and Only Generic Version of RAVICTI® (glycerol phenylbutyrate) Oral Liquid in the United States
Abnormal body odor, including from skin, hair, and urine Retching and gagging Dysgeusia or burning sensation
More news about: Endo USA, Inc.
Oct 20, 2025, 07:00 ET Novo Nordisk to present new data in oral semaglutide 25 mg (Wegovy® in a pill*) and obesity pipeline at ObesityWeek® 2025
injectable) in women's healthAdditional post hoc analyses from OASIS 4 and STEP phase 3a trials examined the efficacy of semaglutide in reducing body weight in women in pre- and post-menopausal stages, and another assessed improved physical function based on patient-reported outcomes data.2,3
More news about: NOVO NORDISK INC.
Oct 20, 2025, 07:00 ET Novo Nordisk to present new data in oral semaglutide 25 mg (Wegovy® in a pill*) and obesity pipeline at ObesityWeek® 2025
injectable) in women's healthAdditional post hoc analyses from OASIS 4 and STEP phase 3a trials examined the efficacy of semaglutide in reducing body weight in women in pre- and post-menopausal stages, and another assessed improved physical function based on patient-reported outcomes data.2,3
More news about: NOVO NORDISK INC.
Oct 20, 2025, 06:10 ET BTL's EMSCULPT NEO Used in Astronaut Training in Hungary for International Space Mission
strength, balance, and recovery. "This technology gave us results beyond traditional training. Medical tests showed muscle hypertrophy, improved body composition, and increased cardiopulmonary fitness," added Dr. Nóra Sydó, who also serves as team doctor for Hungary's Olympic swimming team and
More news about: BTL
Oct 20, 2025, 06:00 ET GRAIL and University of Oxford to Present Long-Term Data From the SYMPLIFY Study Evaluating the Galleri® Multi-Cancer Early Detection Test in Symptomatic Individuals at the Early Detection of Cancer Conference (EDCC)
the importance of continued follow-up to help identify cancers that may initially be missed in diagnostic evaluation. These latest results add to the body of evidence that Galleri could support clinical decision-making in primary care for referral to urgent diagnostic investigations of cancer and drive
More news about: GRAIL, Inc.
Oct 20, 2025, 06:00 ET Chicago and San Diego Campuses of Pacific College of Health and Science (PCHS) to join Southern California University of Health Sciences (SCU)
Health universities—teaching students to blend the best of conventional medicine with proven complementary approaches, and to treat the whole person (body, mind, and spirit). Founded in 1911, SCU has been challenging convention and pushing healthcare forward for more than 100 years. Today, the institution
More news about: Southern California University of Health Sciences
Oct 20, 2025, 04:59 ET BTL's EMSCULPT NEO Used in Astronaut Training in Hungary for International Space Mission
strength, balance, and recovery. "This technology gave us results beyond traditional training. Medical tests showed muscle hypertrophy, improved body composition, and increased cardiopulmonary fitness," added Dr. Nóra Sydó, who also serves as team doctor for Hungary's Olympic swimming team and
More news about: BTL
Oct 20, 2025, 03:43 ET Bulletproof Helmet Market to Reach $2.2 billion, Globally, by 2034 at 5.7% CAGR: Allied Market Research
Marom Dolphin Schuberth Team Wendy EnGarde Body Armor Legacy Safety and Security MARS Armor Protection Group Danmark
More news about: Allied Market Research
Oct 20, 2025, 03:25 ET EXEED Co-Creation Workshop: Texxeract Technology Premieres, Three New Models Debut with the New Family Design Language
philosophy (meaning eternal and unending) draws inspiration from the myth of Atlantis and the dynamics of ocean waves. Through pure, dynamic, and fluid body proportions, sculpted surfaces of light and shadow, and seamless form transitions, the design expresses a sense of timeless beauty and motion. At this
More news about: EXEED
Oct 20, 2025, 02:37 ET Immunotherapy After Surgery Shows Promise in Treating Rare, Aggressive Skin Cancer
centers across the United States from 2018 to 2023. It involved 293 men and women whose Merkel cell tumors had grown or had spread to other areas of the body. Researchers say the study was the largest completed trial to test the role of immunotherapy after surgery. All study participants
More news about: NYU Langone Health System
Oct 20, 2025, 02:31 ET EXEED Co-Creation Workshop: Texxeract Technology Premieres, Three New Models Debut with the New Family Design Language
philosophy (meaning eternal and unending) draws inspiration from the myth of Atlantis and the dynamics of ocean waves. Through pure, dynamic, and fluid body proportions, sculpted surfaces of light and shadow, and seamless form transitions, the design expresses a sense of timeless beauty and motion. At this
More news about: EXEED
Oct 19, 2025, 20:10 ET Ascletis Completes Enrollment in U.S. Phase IIa Study for Its Once-Monthly Subcutaneous Depot Treatment Formulation of Small Molecule GLP-1R Agonist ASC30 for Obesity
double-blind, placebo-controlled and multi-center study conducted in the U.S. to evaluate the safety, tolerability and efficacy in participants with obesity (body mass index (BMI) ≥ 30 kg/m2) or overweight (BMI ≥ 27 kg/m2 but < 30 kg/m2) with at least one weight-related comorbidity.
More news about: Ascletis Pharma Inc.
Oct 19, 2025, 17:15 ET CLARINS & V MAGAZINE CELEBRATE HIGH-PERFORMANCE BEAUTY WITH A STAR-STUDDED GOLDEN HOUR EVENT IN AUSTIN
by Jacques Courtin-Clarins in 1954. Clarins is family-owned and is distributed in more than 150 countries—offering skincare innovations for face and body, men's, and makeup. With unique expertise in Phyto-chemistry, Clarins Laboratories are considered pioneers in the fields of plant science and technology.
More news about: Clarins USA
Oct 19, 2025, 08:45 ET SystImmune Announces iza-bren Meets One of the Dual Primary Endpoints in the BL-B01D1-303 Trial in Recurrent or Metastatic NPC Patients with Results Presented as a Late-Breaking Oral Presentation at ESMO
trial of iza-bren presented at ESMO demonstrated clear clinical benefits of iza-bren compared to traditional chemotherapy. These data add to the growing body of clinical evidence that continues to reinforce our confidence in iza-bren's mechanism of action and therapeutic potential. We believe iza-bren can
More news about: SystImmune, Inc.
Oct 18, 2025, 13:38 ET HKUST Holds Congregation 2025 Conferring Honorary Doctorates on Five Distinguished Leaders
With his novel The Three-Body Problem, Chinese author Mr. Liu became the first Asian writer to win the prestigious Hugo Award for science fiction, earning him international acclaim and a devoted global following. The Three-Body Problem have captivated readers worldwide,
More news about: The Hong Kong University of Science and Technology
Oct 18, 2025, 13:27 ET HKUST Holds Congregation 2025 Conferring Honorary Doctorates on Five Distinguished Leaders
With his novel The Three-Body Problem, Chinese author Mr. Liu became the first Asian writer to win the prestigious Hugo Award for science fiction, earning him international acclaim and a devoted global following. The Three-Body Problem have captivated readers worldwide,
More news about: The Hong Kong University of Science and Technology
Oct 18, 2025, 10:30 ET PADCEV™ Plus KEYTRUDA™, Given Before and After Surgery, Cuts the Risk of Recurrence, Progression or Death by 60% and the Risk of Death by 50% for Certain Patients with Bladder Cancer
of hyperglycemia and DKA occurred in one patient each (0.1%). The incidence of Grade 3-4 hyperglycemia increased consistently in patients with higher body mass index and in patients with higher baseline A1C. The median time to onset of hyperglycemia was 0.5 months (range: 0 to 20 months). Hyperglycemia
More news about: Astellas Pharma Inc.
Oct 18, 2025, 10:00 ET Pomerantz Law Firm Announces the Filing of a Class Action Against Jasper Therapeutics, Inc. and Certain Officers - JSPR
pathway is a survival signal for mast cells and [the Company] believe[s] that blocking this pathway may lead to depletion of these cells throughout the body, including in the lungs and in the skin, which could lead to significant clinical benefit for patients with mast-cell driven diseases such as asthma
More news about: Pomerantz LLP
Oct 18, 2025, 05:03 ET GRAIL PATHFINDER 2 Results Show Galleri ® Multi-Cancer Early Detection Blood Test Increased Cancer Detection More Than Seven-Fold When Added to USPSTF A and B Recommended Screenings
cancers were found in early stages, when cancers are more treatable and potentially even curable. Galleri's ability to accurately predict where in the body the cancer signal comes from also helps to guide a more efficient diagnostic workup," said Josh Ofman, MD, MSHS, President at GRAIL. "These results
More news about: GRAIL, Inc.
Oct 17, 2025, 17:39 ET FDA approves Novo Nordisk's oral semaglutide for cardiovascular (CV) risk reduction in adults with type 2 diabetes who are at high risk, including those who have not had a prior CV event
relative reduction in risk of MACE at 4 years (2% absolute risk reduction at 3 years) compared with placebo.2 These results add to the extensive body of randomized clinical trial and real-world evidence supporting semaglutide. "As the only FDA-approved GLP-1 therapy in a pill,
More news about: Novo Nordisk
Oct 17, 2025, 17:15 ET FDA approves Novo Nordisk's oral semaglutide for cardiovascular (CV) risk reduction in adults with type 2 diabetes who are at high risk, including those who have not had a prior CV event
relative reduction in risk of MACE at 4 years (2% absolute risk reduction at 3 years) compared with placebo.2 These results add to the extensive body of randomized clinical trial and real-world evidence supporting semaglutide. "As the only FDA-approved GLP-1 therapy in a
More news about: Novo Nordisk